Literature DB >> 15728936

Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany.

Doris Hillemann1, Tanja Kubica, Sabine Rüsch-Gerdes, Stefan Niemann.   

Abstract

Genotypic analysis of 103 multidrug-resistant Mycobacterium tuberculosis strains isolated in Germany in 2001 revealed that mutations in codon 531 (75.7%) of the rpoB gene and codon 315 (88.4%) of the katG gene are most frequent. Beijing genotype strains (60.2% of all isolates) displayed a different distribution of resistance mutations than non-Beijing strains.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728936      PMCID： PMC549281          DOI： 10.1128/AAC.49.3.1229-1231.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  The Beijing genotype is emerging among multidrug-resistant Mycobacterium tuberculosis strains from Germany.

Authors:  T Kubica; S Rüsch-Gerdes; S Niemann
Journal:  Int J Tuberc Lung Dis       Date:  2004-09       Impact factor: 2.373

2.  Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level.

Authors:  A Telenti; N Honoré; C Bernasconi; J March; A Ortega; B Heym; H E Takiff; S T Cole
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Usefulness of Mycobacterium tuberculosis genomic mutations in the genes katG and inhA for the prediction of isoniazid resistance.

Authors:  P Dobner; S Rüsch-Gerdes; G Bretzel; K Feldmann; M Rifai; T Löscher; H Rinder
Journal:  Int J Tuberc Lung Dis       Date:  1997-08       Impact factor: 2.373

4.  Disequilibria in the distribution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates from Germany and Sierra Leone.

Authors:  H Rinder; P Dobner; K Feldmann; M Rifai; G Bretzel; S Rüsch-Gerdes; T Löscher
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

5.  Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis.

Authors:  K Mdluli; D R Sherman; M J Hickey; B N Kreiswirth; S Morris; C K Stover; C E Barry
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

6.  Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities.

Authors:  S Sreevatsan; X Pan; Y Zhang; V Deretic; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology.

Authors:  J Kamerbeek; L Schouls; A Kolk; M van Agterveld; D van Soolingen; S Kuijper; A Bunschoten; H Molhuizen; R Shaw; M Goyal; J van Embden
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

8.  Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

Authors:  K Mdluli; R A Slayden; Y Zhu; S Ramaswamy; X Pan; D Mead; D D Crane; J M Musser; C E Barry
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

9.  Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.

Authors:  J M Musser; V Kapur; D L Williams; B N Kreiswirth; D van Soolingen; J D van Embden
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

10.  Silent nucleotide polymorphisms and a phylogeny for Mycobacterium tuberculosis.

Authors:  Lucy Baker; Tim Brown; Martin C Maiden; Francis Drobniewski
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883
View more
  24 in total

1.  Resistance levels and rpoB gene mutations among in vitro-selected rifampin-resistant Mycobacterium tuberculosis mutants.

Authors:  Emma Huitric; Jim Werngren; Pontus Juréen; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany.

Authors:  Sönke Andres; Doris Hillemann; Sabine Rüsch-Gerdes; Elvira Richter
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

3.  Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan.

Authors:  Chiyoji Abe; Ikuo Kobayashi; Satoshi Mitarai; Masako Wada; Yoshiko Kawabe; Tetsuya Takashima; Katsuhiro Suzuki; Li-Hwei Sng; Suxing Wang; Hla Hla Htay; Hideo Ogata
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

4.  Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates.

Authors:  Doris Hillemann; Michael Weizenegger; Tanja Kubica; Elvira Richter; Stefan Niemann
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Evaluation of the rpoB macroarray assay to detect rifampin resistance in Mycobacterium tuberculosis in Beijing, China.

Authors:  I Mokrousov; W W Jiao; G Z Sun; J W Liu; M Li; O Narvskaya; A D Shen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

6.  Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden.

Authors:  Solomon Ghebremichael; Ramona Groenheit; Alexandra Pennhag; Tuija Koivula; Emmi Andersson; Judith Bruchfeld; Sven Hoffner; Victoria Romanus; Gunilla Källenius
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

7.  Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis.

Authors:  I L Bergval; R N C P Vijzelaar; E R Dalla Costa; A R J Schuitema; L Oskam; A L Kritski; P R Klatser; R M Anthony
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

8.  Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.

Authors:  Mai N T Huyen; Frank G J Cobelens; Tran N Buu; Nguyen T N Lan; Nguyen H Dung; Kristin Kremer; Edine W Tiemersma; Dick van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

9.  Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin.

Authors:  Anna Zaczek; Anna Brzostek; Ewa Augustynowicz-Kopec; Zofia Zwolska; Jaroslaw Dziadek
Journal:  BMC Microbiol       Date:  2009-01-15       Impact factor: 3.605

10.  Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance.

Authors:  Indra L Bergval; Anja R J Schuitema; Paul R Klatser; Richard M Anthony
Journal:  J Antimicrob Chemother       Date:  2009-07-04       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.